Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Asthma
Interventions: GSK3511294, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 41
States / cities: Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Miami, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 30
States / cities: Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Conditions: Age-Related Hearing Loss
Interventions: AUT00063, Placebo; Drug
Lead sponsor: Autifony Therapeutics Limited; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Sacramento, California • Colorado Springs, Colorado • Boca Raton, Florida + 10 more

Conditions: Healthy
Interventions: BLKR201, Placebo; Drug
Lead sponsor: Formation Bio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Newport Beach, California • San Diego, California • San Francisco, California + 20 more

Conditions: Asthma
Interventions: VR506, Placebo; Drug
Lead sponsor: Vectura Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more

Conditions: Healthy Volunteer Subjects
Interventions: Trehalose for IV Infusion, Saline 0.9% IV; Drug
Lead sponsor: Bioblast Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Plaque Type Psorisis
Interventions: Tapinarof Cream 1%, VTAMA®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more

Conditions: Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Interventions: NBI-827104, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Androgenetic Alopecia
Interventions: AH-001 or placebo; Drug
Lead sponsor: AnHorn Medicines Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions: BIO101, Placebo; Drug
Lead sponsor: Biophytis; Industry
Eligibility: 65 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 19
States / cities: Banning, California • Garden Grove, California • San Diego, California + 15 more

Conditions: Primary Hyperoxaluria
Interventions: Oxalobacter formigenes, Placebo; Biological · Drug
Lead sponsor: OxThera; Industry
Eligibility: 5 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Secondarily Infected Traumatic Skin Lesions
Interventions: Mupirocin Calcium, Vehicle; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Months and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Celiac Disease
Interventions: PRV-015, Placebo; Biological · Other
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Los Angeles, California • Ventura, California • Denver, Colorado + 25 more

Conditions: Thoracic Aortic Aneurysms, and Penetrating Atherosclerotic Ulcers
Interventions: Relay Thoracic Stent-Graft, Open Repair; Device · Procedure
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 22 more

Conditions: Moderate Plaque Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 45
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 34 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatitis C
Interventions: miravirsen, saline; Drug
Lead sponsor: Santaris Pharma A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Major Depressive Disorder
Interventions: NBI-1070770, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 13
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Lemon Grove, California + 10 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, 5 mg + insulin, Placebo + insulin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Tempe, Arizona • Fresno, California • Lomita, California + 13 more

Conditions: Osteoarthritis Pain of the Knee
Interventions: Diclofenac sodium active topical patch, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Clearwater, Florida • Doral, Florida + 7 more

Conditions: Spinal Cord Injuries
Interventions: Heated Vest, Non-Heated Vest; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 68 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

A Phase 1 Study of BLKR201 in Healthy Adult Participants

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Heated Vest for Persons With Spinal Cord Injury